New AACE guideline outlines safe use of advanced diabetes technology Source:
Grunberger G. Clinical Practice Guideline – Use of advanced technology in management of persons with diabetes mellitus. Presented at: American Association of Clinical Endocrinology Annual Scientific and Clinical Conference; May 26-29, 2021 (virtual meeting). Disclosures: Grunberger reports he has received speakers’ fees from Abbott, Eli Lilly and Novo Nordisk. Please see the guideline for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
Search jobs 27-May-2021 PureTech Founded Entity Gelesis Presents Findings on Plenity®-Induced Weight Loss at the American Association of Clinical Endocrinology (AACE) 2021 Annual Virtual Meeting
PureTech Founded Entity Gelesis Presents Findings on
Plenity®-Induced Weight Loss at the American Association of Clinical Endocrinology (AACE) 2021 Annual Virtual Meeting
Analysis showed that treatment for weight management with Plenity
resulted in NALFD Fibrosis Score Improvement
These data support further clinical investigation using Gelesis’ superabsorbent hydrogel platform for the potential treatment of metabolic-related liver disease
First patient to enroll in a clinical trial leveraging this platform technology for treatment of NASH/NAFLD later this year
email article
A more gradual increase in oral osilodrostat (Isturisa) dosing was better tolerated among patients with Cushing s disease, compared with those who had more accelerated increases, a researcher reported.
Looking at outcomes from two phase III trials assessing osilodrostat, only 27% of patients had hypocortisolism-related adverse events if dosing was gradually increased every 3 weeks, said Maria Fleseriu, MD, of Oregon Health & Science University in Portland, in a presentation at the virtual meeting of the American Association of Clinical Endocrinology (AACE).
On the other hand, 51% of patients experienced a hypocortisolism-related adverse event if osilodrostat dose was increased to once every 2 weeks.